GM-CSF Antibody [Unconjugated]

Recombinant Mouse GM‑CSF (Catalog # 415-ML) stimulates proliferation in the DA3 mouse myeloma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse GM‑CSF (0.75 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse GM‑CSF Antigen Affinity-purified Polyclonal Antibody (Catalog # AF‑415‑NA). The ND50 is typically 0.01‑0.03 µg/mL.

• Reactivity: Mu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

GM-CSF Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant mouse GM-CSF
  Ala18-Lys141
  Accession # Q14AD9
• Specificity: Detects mouse GM-CSF in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CSF2
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.01-0.03 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for GM-CSF Antibody [Unconjugated]

• colony stimulating factor 2 (granulocyte-macrophage)
• Colony-stimulating factor
• CSF
• CSF2
• CSF-2
• GMCSF
• GM-CSF
• GMCSFgranulocyte-macrophage colony-stimulating factor
• granulocyte-macrophage colony stimulating factor
• MGC131935
• MGC138897
• Molgramostim
• molgramostin
• Sargramostim

Background

GM-CSF was initially characterized as a factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils. GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity. It shows clinical effectiveness in ameliorating chemotherapy-induced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines. The 22 kDa glycosylated GM-CSF, similar to IL-3 and IL-5, is a cytokine with a core of four bundled alpha ‑helices. Mature mouse GM-CSF shares 49-54% amino acid sequence identity with canine, feline, human, and porcine GM-CSF and 69% with rat GM-CSF. GM‑CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF R alpha /CD116 and the signal transducing common beta chain (CD131) which is also a component of the high-affinity receptors for IL-3 and IL-5. In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF R alpha . The activity of GM-CSF is species specific between human and mouse. Mouse GM-CSF is only weakly active on rat cells, although rat GM-CSF is fully active on mouse cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for GM-CSF Antibody (AF-415-NA)(6)

Publications using AF-415-NA

• Daniela C. Ivan, Sabrina Walthert, Giuseppe Locatelli Central Nervous System Barriers Impact Distribution and Expression of iNOS and Arginase-1 in Infiltrating Macrophages During Neuroinflammation Frontiers in Immunology 2021-04-15 [PMID: 33936108]
• Pennati A, Deng J, Galipeau J Maltose-binding protein fusion allows for high level bacterial expression and purification of bioactive mammalian cytokine derivatives. PLoS ONE, 2014-09-08;9(9):e106724. 2014-09-08 [PMID: 25198691] (Western Blot, Mouse)
• Zhou Q, Ho A, Schlitzer A, Tang Y, Wong K, Wong F, Chua Y, Angeli V, Mortellaro A, Ginhoux F, Kemeny D GM-CSF-licensed CD11b+ lung dendritic cells orchestrate Th2 immunity to Blomia tropicalis. J Immunol, 2014-06-18;193(2):496-509. 2014-06-18 [PMID: 24943219] (Neutralization, Mouse)
• Rafei M, Wu JH, Annabi B, Lejeune L, Francois M, Galipeau J A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex. Blood, 2006-11-02;109(5):2234-42. 2006-11-02 [PMID: 17082320] (Western Blot, Mouse)
• Dumas C, Muyombwe A, Roy G, Matte C, Ouellette M, Olivier M, Papadopoulou B Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect. Immun., 2003-11-01;71(11):6499-509. 2003-11-01 [PMID: 14573672] (Neutralization, Mouse)
• Shih CC, Hu MC, Hu J A secreted and LIF-mediated stromal cell-derived activity that promotes ex vivo expansion of human hematopoietic stem cells. Blood, 2000-03-15;95(6):1957-66. 2000-03-15 [PMID: 10706861] (Neutralization, Mouse)

Bioinformatics

• Gene Symbol: CSF2
• Uniprot:
  • Q14AD9()